Paragangliomas (PGLs) and pheochromocytomas (PCCs) are rare neuroendocrine tumors with an incidence estimated to be less than 1 per 300 000 persons per year. PGLs are tumors derived from the paragangliomic system and may be localized from the skull base to the pelvic floor in contrast to PCCs that are located at the level of the adrenal glands. They can be sporadic or part of a genetic or familial syndrome. More than 40% of cases with PCCs and PGLs harbor a germline mutation in one of the known susceptibility genes ([@B1]).

Genes associated with an increased risk of developing PGLs and PCCs include *VHL*, *RET*, *NF1*, the genes encoding the four subunits of the mitochondrial enzyme succinate dehydrogenase: *SDHD*, *SDHB*, *SDHC*, and *SDHA*, the assembly factor *SDHAF2*, and, recently, *TMEM127*, *MAX*, *FH*, *EPAS1*, and *MDH2* genes ([@B1]). Mutations in *SDHB* and *SDHD* genes are usually the most common. *SDHC* mutations are rare, encompassing only 7% of hereditary PGLs/PCCs ([@B2]).

There is a well-documented founder effect in the French-Canadian (FC) population of the province of Québec. The genetic status of the PGL/PCC population has never been studied in the FC population. We investigated the genetic profile of FC subjects with PGLs. Surprisingly, the same *SDHC* mutation was identified in 10 apparently unrelated patients. We provide detailed clinical and paraclinical parameters of these 10 patients and three of their relatives. Then we performed a genealogical reconstruction of the 10 index cases reported to evaluate genetic contribution of ancestors of these apparently unrelated cases. We found that the index cases are more related than the control group and that their common ancestors are immigrants or parents of immigrants from France, supporting that the *SDHC* mutation identified in FC patients is originating from France.

Materials and Methods
=====================

FC patients with PGLs
---------------------

Genetic testing has been offered to patients affected by PGLs since 2005 seen at our adrenal genetics clinic at Centre hospitalier de l\'Université de Montréal (CHUM). The clinical details of the investigated patients are given in [Table 1](#T1){ref-type="table"}. One previously reported patient was referred to us from McGill University and was included in the genealogical reconstruction study described below ([@B3]). Written informed consent for genetic testing was obtained from each patient. The study was approved by the Institutional Review Board of the CHUM (Montréal, Canada).

###### 

Clinical Details of the Investigated FC Patients With the *SDHC* \[c.397C\>T, p.(Arg133Ter\]) Mutation and PGLs

  Index Cases    Age, y   Sex   Family History   Parental Transmission         Initial Localization                                              Isolated or Multiple   Malignant                            Tumor Size, cm                            Secretion   U Norepi (N \< 440 nmol/d)   U Epi (N \< 110 nmol/d)   U Dopa (N \< 2570 nmol/d)                      U Normeta (N 240)   U Meta (N \< 275 nmol/d)   MIBG   Octreo-scan   PET
  -------------- -------- ----- ---------------- ----------------------------- ----------------------------------------------------------------- ---------------------- ------------------------------------ ----------------------------------------- ----------- ---------------------------- ------------------------- ---------------------------------------------- ------------------- -------------------------- ------ ------------- -----
  IC1            37       M     No               Unknown                       Retrocardiac left paraaortic                                      Multiple               No                                   5 × 3.2 × 2.5 3.5 × 3 × 1.5 4.7 × 3 × 2   S           **2145**                     \<33                      1168                                           **2277**            172                        No     No            Yes
  IC2            52       F     No               Paternal obligatory carrier   HN R carotid body                                                 Isolated               No                                   4 × 3.5 × 2,3                             S           **855**                      151                       **3787**^[a](#TF1-1){ref-type="table-fn"}^     **605**             83                         No     Yes           NA
  IC3            23       F     Yes              Paternal                      Intrapericardial                                                  Isolated               No                                   3.5 × 3 × 2                               S           **10 800**                   \<12                                                                     **28 704**          **559**                    No     Yes           Yes
  IC4            66       F     No               Unknown                       Anterior and mean mediastinal with extension in the left atrial   Isolated               Malignant multiple bone metastases   8.5 × 10 × 10                             NS          326                          41                        2097                                           176                 49                         Yes    NA            Yes
  IC5            32       M     Yes              Maternal obligatory carrier   HN L carotid                                                      Isolated               No                                   4.5 × 4.2 × 2.2                           ND          NA                           NA                        NA                                             NA                  NA                         NA     NA            NA
  IC6            41       F     No               Maternal                      HN R jugulare                                                     Isolated               Malignant; Locally invasive          3,7 × 2,1                                 S           **3363**                     116                       **6104**                                       **1539**            226                        NA     NA            NA
  IC7            49       M     No               Paternal                      HN L: vagal R: carotid                                            Multiple               No                                   L: 7.2 × 3.8 × 4.6 R: 1.1 × 1.4           NS          N                            N                         N                                              N                   N                          NA     NA            NA
  IC8            54       F     No               Unknown                       HN L tympanojugular                                               Isolated               No                                   1.5 × 1 × 0.7                             NS          141                          12                        168                                            117                 71                         NA     NA            NA
  IC9            34       F     No               Paternal obligatory carrier   HN R carotid                                                      Isolated               Malignant multiple bone metastases   3 × 2 × 2                                 S           **784**                      56                        **61 371**^[b](#TF1-2){ref-type="table-fn"}^   **412**             107                        No     Yes           Yes
  IC10           57       M     No               Unknown                       HN carotid-jugulare space                                         Isolated               No                                   6 × 3.5 × 2.8                             S           428                          56                        **44 15**^[c](#TF1-3){ref-type="table-fn"}^    180                 179                        NA     NA            Yes
  R IC3          40       M     Yes              Paternal obligatory carrier   HN carotid-jugulare space                                         Isolated               No                                   3.9 × 3.5 × 2.2                           NS          N                            N                         N                                              N                   N                          NA     NA            NA
  R IC5          47       M     Yes              Paternal                      HN R vagal                                                        Isolated               No                                   6.5 × 2.5 × 1.5                           NS          415                          31                        **3508**                                       319                 185                        NA     NA            NA
  Father R IC5   81       M     Yes              Unknown                       HN L carotid                                                      Isolated               No                                   0.8                                       NS          N                            N                         N                                              N                   N                          NA     NA            Yes

Abbreviations: F, female; HN, head and neck; IC, index case; L, left; M, male; MIBG, (^123^I)metaiodobenzylguanidine; N, normal; NA, not available; ND, not determined; NS, nonsecreting; R, right; R IC, related of index case; S, secreting; U, urinary.

Dosage of 9 948 nmol/d urinary methoxytyramine N \< 1450.

Plasma methoxytyramine: 12.4 nmol/L N \< 0.17.

Plasma methoxytyramine: 1.6 nmol/liter N \< 0.17.

Bold indicates abnormal values.

Genetic analysis of PGL-related genes
-------------------------------------

After genetic counseling, 29 FC patients with PGLs asked for PGL genetic testing and signed informed consent. After blood sampling, germline DNA was extracted from leukocytes and then sent to the Genetic department of Hôpital Européen Georges Pompidou (Paris, France). The genetic testing was done in that expert laboratory by direct sequencing, quantitative multiplex PCR of short fluorescent fragments, and specific multiplex ligation-dependent probe amplification as previously described ([@B2], [@B4], [@B5]). Over the years, several PPGL-related genes were analyzed for each patient; however, in the last few years, we observed the high prevalence of the *SDHC* mutation in our cohort of FC patients; thus, the *SDHC* gene analysis was prioritized in our population using the sequential specific genetic testing approach.

Genealogical reconstruction
---------------------------

To get a better understanding of the origins of the *SDHC* mutation, we carried out a genealogical reconstruction study. All index cases carrying the *SDHC* mutation accepted to participate in the genealogical reconstruction study and signed a specific informed consent. Each index case provided the following information required for maternal and paternal lineage reconstruction: name, date of birth, and dates and parishes of marriages of maternal and paternal ancestors. Then the ascending genealogies were reconstructed for each individual to the ancestors who settled in Nouvelle France. This was performed at the University of Québec in Chicoutimi by Project BALSAC using the BALSAC population. The BALSAC population register and its peripheral databases contain linked genealogical information on nearly 340 000 individuals married in the province of Québec between the beginning of the 17th century and the present day (Vézina H, Projet BALSAC-Rapport annual report, 2013--2014; Chicoutimi \[Québec\] \[<http://balsac.uqac.ca/>\]). Reconstruction was performed for the first immigrants to Canada (10 generations ago). Each case was matched to three different controls based on place and year of marriage of their parents. Thirty controls were selected in the BALSAC-RETRO database for comparison. The goal was to determine whether the genealogical characteristics of individuals carrying the *SDHC* mutation were related to their status or whether they merely depicted the underlying population structure, and the genealogies were analyzed using various software programs developed at the University of Québec in Chicoutimi.

Kinship coefficient and genetic contribution
--------------------------------------------

The kinship coefficient and genetic contribution between probands were calculated as previously described ([@B6]). The kinship coefficient between two individuals (B1 and B2) represents the probability that one allele from individual B1 is identical by descent to an allele from individual B2 picked at random at the same locus and is calculated as follows: $$\Phi\left( {\text{B}_{1},\text{B}_{2}} \right) = {\sum\limits_{A}{\sum\limits_{C}{1/2^{n{({A,C})} + m{({A,C})} + 1}\left( {1 + F\left( A \right)} \right)}}}$$ where A is a common ancestor of B1 and B2; C is the number of genealogical paths between B1 and B2; m(A, C) is the number of generations separating the founder A from the individual B1 for each path; n(A, C) is the number of generations separating the founder A from the individual B2 for each path; and F(A) is the inbreeding coefficient of the founder A. The mean kinship coefficient for a group of individuals is the kinship coefficient divided by the total number of pairs of individuals.

The genetic contribution of an ancestor represents the sum of transmission probabilities of one gene to each individual of a given group and their genetic contribution to the carriers\' group and to the three control groups. Calculation of the genetic contribution of an ancestor to a set of probands S is calculated as follows: $$GC = {\sum\limits_{s}{\sum\limits_{p}\left( {1/2} \right)^{g}}}$$ where s is the number of individuals in a given group genealogically related to the ancestor; p is the number of genealogical paths between the ancestor and the individual; and g is the number of generations separating the ancestor from the individual. The mean genetic contribution per individual is the genetic contribution divided by the number of individuals.

Results
=======

Genetic characterization of FC patients with PGLs
-------------------------------------------------

Twenty-nine FC patients with histologically proven PGLs seen at our adrenal genetics clinic at CHUM (IB) accepted, after information, to perform genetic analysis of PGL susceptibility genes. Thirteen of 29 patients (44.8%) carried a germline mutation. The same heterozygous nonsense mutation at codon 133 of exon 5 of the *SDHC* gene (c.397C\>T, p.\[Arg133Ter\]) was found in nine patients representing 69.2% of the patients having a germline mutation and 31% of all FC patients evaluated for PGL genetic testing. The *SDHC* nonsense mutation (c.397C\>T, p.\[Arg133Ter\]) leads to an amino acid changed from arginine to a stop codon, causing premature truncation of the protein. Among the four other FC patients with PGLs carrying a germline mutation, there were two patients with a *SDHD* mutation (c.112C\>T, p.\[Arg38Ter\] and c.119_125del, p.\[Ile240AsnfsX44\]), one patient with a *SDHB* mutation (c.137G\>A, p.\[Arg46Gln\]), and one patient with PCCs and PGLs due to a *FH* mutation (c.268-2A\>G, p.\[?\]). This last patient has been reported previously ([@B7]).

Clinical characteristics of FC patients carrying a *SDHC* mutation
------------------------------------------------------------------

Clinical and paraclinical characteristics of the nine index cases of our cohort of FC patients, in addition of the case referred to us from McGill University in Montreal (IC7) ([@B3]) carrying the (c.397C\>T, p.\[Arg133Ter\]) *SDHC* mutation, are summarized in [Table 1](#T1){ref-type="table"}. The average age at the first diagnosis was 44.5 years (ranging from 23 to 66 y). PGLs were isolated and localized in the head and neck (HNPGL) (n:7), in the thorax (n:2), in the pericardium (n:1), and in the mediastinum (n:1). One patient had multiple PGLs located in retrocardiac position and in the abdomen. A 49-year-old male had a bilateral HNPGL. Three of seven HNPGLs were considered as malignant: a PGL originating from the glomus jugulare that was locally invasive in the mastoid bone (IC6) and two PGLs (IC4 and IC9) with multiple bone metastases. IC4 was metastatic at the initial work-up, and IC9 who has been operated on a carotid PGL at 34 years old was diagnosed 12 years later with multiple bone metastases associated with elevated dopamine levels. Urine noradrenaline, normetanephrines, and/or dopamine levels were elevated in six patients including three patients with HNPGLs, whereas HNPGLs are usually reported to be associated with a catecholamine secretion in less than 5% of cases. Plasma methoxytyramine levels were available for two patients and were in both cases highly elevated (IC9, 12.4 nmol/L \[N \< 0.17\]; and IC10, 1.6 nmol/L). (^123^I)metaiodobenzylguanidine was positive in one of five cases, ^111^In-labeled pentetreotide scan (OctreoScan) in three of four cases, and FDG-PET in five of five patients.

Mode of transmission and penetrance of the disease
--------------------------------------------------

Within the 10 index cases, three individuals had a family history of PGLs. Patient IC5 had a familial history of HNPGLs for the sister of his maternal grandmother ([Figure 1](#F1){ref-type="fig"}A) and the son of a brother of his maternal grandmother (RIC5). Patient IC8 had a sister with a HNPGL, and one son of this sister was known to suffer a PGL (unknown location). At the initial interview, patient IC3 did not report any familial history of PGL but a sudden death event in a sister of her paternal grandfather. Then the half-brother of her father developed a HNPGL at 41 years of age ([Figure 1](#F1){ref-type="fig"}B). Within these three families, the disease, as well as the *SDHC* mutation, both follows an autosomal mode of transmission.

![Familial pedigrees of patients IC5 (A) and IC3 (B). The arrow shows the index patient with paraganglioma carrying the *SDHC* mutation (c.397C\>T). Squares, men; circles, women; black figures, individuals with PGL; white figures with a black circle in the middle, asymptomatic carriers; +, carrier of the *SDHC* mutation; −, no carrier of the *SDHC* mutation.](zeg0111629050001){#F1}

Parental transmission has been confirmed by genetic analysis in four index cases: paternal branch (n:3) and maternal branch (n:1). In addition, the fathers were obligatory carriers in two cases and the mother in one case. Both maternal and paternal transmission was observed in the family of IC5; moreover, IC3 developed an intrapericardial PGL, whereas her paternal uncle developed a HNPGL, suggesting that the *SDHC* mutation may be associated with variable expressivity within a same family.

Familial screening of first-degree family members of the index cases with (c.397C\>T, p.\[Arg133Ter\]) *SDHC* mutation
----------------------------------------------------------------------------------------------------------------------

First-degree relatives of index cases were offered a predictive genetic testing for the presence of germline *SDHC* mutation. Three parents (two fathers and one mother) were determined as being carriers of the mutation. Clinical investigations including plasmatic metanephrines, normetanephrines, and chromogranin A levels and urinary catecholamines in addition to head and neck, thoracic, and abdominal imaging were negative for two of them. An 8-mm nonsecreting left carotid HNPGL had been found 2 years before the genetic testing in the father of IC5 and was then confirmed to be a unique tumor by ^18^F-fluorodeoxyglucose-PET. The *SDHC* mutation was identified in six of nine children of index cases, and in all cases no tumor has been diagnosed. All mutation carriers are currently followed up with biochemical investigation annually and imaging every 2--3 years.

Ascending genealogical reconstruction
-------------------------------------

Up to the third generation, there were no common ancestors between probands. However, a geographical concentration was revealed. Actually 60% of the parents, 55% of the grandparents, and 50% of the great-grandparents of the 10 index cases were married in des Bois Francs region in the province of Québec followed by the Lanaudière region where 10% of the parents, 10% of the grandparents, and 10% of the great-grandparents were married.

Starting at generation 4, the index cases are more related than the control groups as shown in [Figure 2](#F2){ref-type="fig"}, in which kinship coefficient are higher among index cases than among each of the three control groups, indicating that the probability for index individuals to share an allele identical by descent at the same locus is greater than that of controls.

![Mean kinship coefficients for the *SDHC* carriers (red bars) and for the three groups of controls (controls 1, green bars; controls 2, purple bars; controls 3, blue bars). Starting at generation 4, the kinship coefficients were higher in the group of *SDHC* carriers compared with the three control groups, indicating that the index cases are more related than the control groups.](zeg0111629050002){#F2}

We found 22 common ancestors to the 10 index cases, starting from the eighth generation. They are immigrants or parents of immigrants from France at the beginning of the 17th century, supporting that the *SDHC* mutation (c.397C\>T, p.\[Arg133Ter\]) is originating from France. These 22 common ancestors are regrouped in four large families including couples with their parents and grandparents. The four more contemporary couples are described in [Table 2](#T2){ref-type="table"}.

###### 

Mean Genetic Contribution of the Common Ancestors in the 10 Index cases (IC) Carrying the *SDHC* Mutation and the 3 Control Genealogies

  Ancestors   Mean Genetic Contribution per Individuals   Genetic Contribution IC/Mean of Controls                                                                                       
  ----------- ------------------------------------------- ------------------------------------------ ----------- ----------- ----------- ----------- ----------- ----------- ----------- ------
  D           M                                           Montréal, Canada                           1654        France      Immigrant   0.003 540   0.003 247   0.001 428   0,000 720   1.97
  F           France                                      Immigrant                                  0.003 540   0.003 247   0.001 428   0,000 720   1.97                                
  E           M                                           France                                     1628        France      Immigrant   0.003 882   0.002 917   0.002 948   0,002 759   1.35
  F           France                                      Immigrant                                  0.003 882   0.002 917   0.002 948   0,002 759   1.35                                
  F           M                                           France                                     1622        France      Immigrant   0.002 570   0.002 856   0.001 337   0,002 191   1.21
  F           France                                      France                                     0.002 570   0.002 856   0.001 337   0,002 191   1.21                                
  A           M                                           Québec, Canada                             1653        France      Immigrant   0.000 964   0.000 610   0.000 537   0,000 464   1.80
  F           France                                      Immigrant                                  0.001 990   0.002 002   0.002 148   0,002 710   0.87                                

Abbreviations: C1, C2, C3, control genealogies; F, female; IC, index case; M, male. The mean genetic contribution of couple D to each index case is of 0.003 540. This means that the probability that the index case had received the mutated *SDHC* allele from this ancestor is of 0.003 540, which suggest that each index case has a chance on 282 to have received the *SDHC* mutated gene from this ancestor.

Then, to determine which couple most likely represented the common ancestor to each proband heterozygous for the *SDHC* mutation (c.397C\>T, p.\[Arg133Ter\]), we compared the genetic contribution of those four couples with three control genealogies ([Table 2](#T2){ref-type="table"}). Ancestors of couples A, D, E, and F showed a higher mean genetic contribution in the index cases compared with the control groups except for the female of couple A, who showed a higher genetic contribution in the controls.

All individuals of these four couples were born in France. Two couples were married in France, and two others were married in Nouvelle France (one in Québec City in 1654 and one in Montréal City in 1653) after immigration. The French origin of the *SDHC* mutation (c.397C\>T, p.\[Arg133Ter\]) has been confirmed by the genetics laboratory of Hôpital Européen Georges Pompidou that previously identified the *SDHC* mutation (c.397C\>T, p.\[Arg133Ter\]) in five French affected cases (four unrelated): four males and one female aged of 35, 36, 38, 66, and 72 years at diagnosis. All developed an HNPGL. A 35-year-old male (patient 2) had a locally invasive tumor as found in IC6 ([Table 3](#T3){ref-type="table"}).

###### 

Clinical Details of the Investigated French Patients With the *SDHC* (c.397C\>T, p.\[Arg133Ter\]) Mutation With Paragangliomas

  Cases Department of Birth   Age at Diagnosis, y   Sex   Family History            Parental Transmission   Initial Localization   Unique or Multiple   Malignant          Location          Tumor Size, cm   Secretion
  --------------------------- --------------------- ----- ------------------------- ----------------------- ---------------------- -------------------- ------------------ ----------------- ---------------- -----------
  Patient 1 Loiret            36                    M     No                        Paternal                HN                     Unique               N                  Vagal             5                NS
  Patient 2 Seine-Maritime    35                    M     No                        Maternal                HN                     Unique               Locally invasive   Jugulocarotid     5                NS
  Patient 3 Paris             38                    M     No                        Maternal                HN                     Multiple             N                  Tympanojugulare   L:4 R:1,7        NS
  Patient 10 Landes           72                    F     No                        Unknown                 HN                     Unique               Locally invasive   Tympanojugulare   NA               NA
  Patient 12 Eure-et-Loir     66                    M     Yes Father of patient 1   Unknown                 HN                     Unique               N                  Vagale            4                NS

Abbreviations: F, female; HN, head and neck; L, left; M, male; NA, not available; NS, nonsecreting; R, right.

Discussion
==========

We report here the clinical characteristics of a cohort of 18 patients ([Tables 1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}) affected by PGLs caused by a *SDHC* mutation, including 10 FC index cases and three affected relatives of those, and four French index cases with one of their relatives. All are carrying the *SDHC* mutation (c.397C\>T, p.\[Arg133Ter\]). The *SDHC* mutation related to PGLs, which is referred to as paraganglioma type 3, was first described in 2000 by Niemann and Muller ([@B8]). In the last decade, *SDHC* mutations were believed to be associated mainly with head and neck PGLs ([@B9]). In 2014, Else et al ([@B10]) described a cohort of eight patients with PGLs caused by various *SDHC* mutations. Three of those patients had mediastinal PGLs. In the cohort reported here, 3 of 10 index cases have mediastinal PGLs located close to the heart in all cases; one was intrapericardial, one retrocardiac, and one originating from the mediastinum with an extension to the left atrial. In our entire cohort of 18 patients, in contrast to the cohort of Else et al, in which there were no cases of malignancy, 5 of 18 cases (28%) had malignant disease including three patients with locally invasive HNPGLs, a 34-year-old woman who was diagnosed with HNPGLs and developed secondary multiples bone metastases that were diagnosed 12 years later and a 66-year-old female with mediastinal PGLs that showed multiple bone metastases at diagnosis. These cases of malignant disease represent 28% of our large cohort of patients, indicating for the first time that *SDHC*-related PGLs may be frequently malignant and underlying that these patients should be followed up all their lives. Whether the malignant phenotype is specific to the *SDHC* mutation (c.397C\>T, p.\[Arg133Ter\]) or to all *SDHC* mutations will have to be determined.

*SDHC* mutations are infrequent worldwide in patients with PGLs, and this is contrasting with the high prevalence of *SDHC* mutation found in 31% of our FC cohort of PGLs. To our knowledge, only six other cases carrying the *SDHC* mutation (c.397C\>T, p.\[Arg133Ter\]) associated with PGLs have been described so far. Three unrelated patients were described previously by a German team ([@B11]) and three from the United States into three different reports ([@B10], [@B12], [@B13]) ([Table 4](#T4){ref-type="table"}). The ethnical origin of these cases was not described. Within these six described cases, there were five patients with HNPGLs ([@B10][@B11][@B13]) including a 66-year-old male with an aggressive invasive temporal bone PGL ([@B13]) and one patient in the study by Bickmann et al ([@B11]), similar to our patient IC4 with a large mediastinal PGL infiltrating the left ventricular myocardium with bone metastases. One HNPGL case was reported by Zbuk et al ([@B12]), who described a woman with epithelial thyroid cancer and carotid PGL who carried in addition to the *SDHC* mutation a germline *PTEN* mutation. Four of six HNPGLs cases were secreting tumors, which is much higher than the former admitted level of 5% secreting HNPGLs: two secreted mainly noradrenaline and normetanephrine and two others secreted very high levels of dopamine and methoxytyramine. These findings understress that all individual diagnosed with *SDHC*-related HNPGLs should have a biochemical evaluation including methoxytyramine and/or dopamine levels. Although dopamine does not lead to high blood pressure and does not necessitate antihypertensive medications prior to surgery, it may become a tumor marker in the follow-up of these patients.

###### 

Clinical Details of Six Unrelated Patients (Three From Germany and Three From the United States) Who Were Described Previously Carrying the *SDHC* (c.397C\>T, p.\[Arg133Ter\]) Mutation

  Reference                       Country         Age at Diagnosis y   Sex   Family History   Parental Transmission   Initial Localization         Isolated or Multiple   Malignant               Tumor Size, cm        Secretion                 Comments
  ------------------------------- --------------- -------------------- ----- ---------------- ----------------------- ---------------------------- ---------------------- ----------------------- --------------------- ------------------------- ---------------------------------------------------
  Bickmann et al, 2014 ([@B11])   Germany         51                   F     No               NA                      Mediastinal PGL              Isolated               Y bone metastases       NA                    NS                        
  Bickmann et al, 2014 ([@B11])   Germany         57                   M     No               NA                      HN R jugular                 Isolated               No                      NA                    NA                        Suspicion of a left adrenal pheochromocytoma
  Bickmann et al, 2014 ([@B11])   Germany         45                   F     No               NA                      HN L carotid bifurcation     Isolated               No                      NA                    NA                        
  Zbuk et al, 2007 ([@B12])       United States   37, 39               F     No               NA                      HN L carotid and R carotid   Multiple               No                      3 cm and 3 × 1.5 cm   NS                        Germline *PTEN* mutation papillary thyroid cancer
  Else et al, 2014 ([@B10])       United States   30                   F     No               NA                      HN jugular                   Isolated               No (local recurrence)   NA                    NA                        
  Isaacson et al, 2015 ([@B13])   United States   66                   M     No               NA                      HN L temporal bone           Isolated               Yes locally invasive    4.8 × 5.3 × 6.2 cm    Yes, NE and NM elevated   Primary hyperparathyroidism (adenoma)

Abbreviations: F, female; HN, head and neck; L, left; M, male; NA, not available; NE, norepinephrines; NM, normetanephrines; NS, nonsecreting; R, right.

The fact that the *SDHC* (c.397C\>T, p.\[Arg133Ter\]) mutation was recurrent in our FC cohort led us to hypothesize that this mutation might have a single origin. Using a genealogical ascending reconstruction study, we found that the apparently unrelated 10 index cases were more genetically related than the control groups. The *SDHC* (c.397C\>T, p.\[Arg133Ter\]) mutation was most likely introduced by a couple of settlers from France in the 17th century and has been enriched to the FC population as a result of a founder effect. The limited number of founders, which is estimated during the peak of French immigration of approximately 3380 pioneers settled permanently in the St Lawrence River Valley in La Nouvelle France, constitutes the basis for the unique genetic background of the FC population leading to FC founder mutations in various diseases and now in PGLs.

Some evidence for the founder effect in *SDHx* genes have been reported in other populations; founder mutations in the *SDHAF2*, *SDHB*, and *SDHD* genes were described in The Netherlands ([@B14], [@B15]) and in the *SDHD* gene in an area of central Italy ([@B16]) and Austria ([@B17]). However, to our knowledge we report here the first founder effect in the *SDHC* gene.

The prevalence of PGLs is unknown in the Province of Québec, but the early introduction of the *SDHC* (c.397C\>T, p.\[Arg133Ter\]) mutation in the Québec settlement process could imply that this mutation has a high prevalence in the FC population. The fact that 7 of 10 index cases with founder *SDHC* mutation present without a family history of PGLs suggests a low penetrance of the *SDHC* mutation, which is supporting by that among nine carriers of *SDHC* mutation, we found no PGLs except for a 80-year-old man who was diagnosed with a small HNPGL 2 years prior the genetic screening.

Genetic screening in the FC population should take into account the unusually high prevalence of the *SDHC* founder mutation. This study should significantly simplify the molecular testing and clinical management of FC patients with PGLs and provide new clinical and paraclinical data on the rare *SDHC*-related PGLs.

Abbreviations: CHUMCentre Hospitalier de l\'Université de MontréalFCFrench CanadianHNPGLPGLs localized in the head and neckPCCpheochromocytomaPETpositron emission tomographyPGLparaganglioma.
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